In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genomics Collaborative Inc.

Latest From Genomics Collaborative Inc.

Deal Statistics Quarterly, Q2 2004

Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.

BioPharmaceutical Medical Device

Fibromyalgia: The Newest Psychiatric Market

Cypress Bioscience has reinvented itself in the past year to focus on the development of drugs for fibromyalgia syndrome, a mysterious disease characterized by pain and sleeplessness in the absence of measurable pathophysiological features.

BioPharmaceutical Strategy

Start-Up Previews (7/01)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups focus on Biorepositories (Asterand Inc., BioSample Inc., Genomics Collaborative Inc., TissueInformatics Inc.); Therapeutics for Diabetes and Obesity (Arexis AB, Diabetogen Biosciences Inc., PanCel Corp., Rademacher Group Ltd.); and Orthopedic and Surgical Devices (Ascension Orthopedics Inc., Coapt Systems Inc., NuVasive Inc., SpringFlex Orthopedics Inc.). Plus these Selected Start-Ups across Health Care: Achillion Pharmaceuticals Inc., GeneProt Inc., MonitorForHire.com and Targacept Inc.

Biorepositories

Despite the in silico research ideals of many genomicists, no one has yet found a way around the basic requirement for using human tissue in gene expression studies-a broad array of it, well characterized, from healthy and diseased patients, and from world populations at large. That's why start-ups, drug discovery firms and others are creating a new resource: biorepositories--banks of tissue samples and data to serve the diagnostic, pharmaceutical and tissue engineering industries. As providers of services and products to research-based companies, these companies believe they are operating in a market that ranges from $500 million to $5 billion.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
UsernamePublicRestriction

Register